Skip to main content
Greg Vontz

Greg Vontz

CEO, Leapfrog Bio
United States
Mr. Vontz has over 30 years of experience in the biotechnology and pharmaceutical industry. Mr. Vontz currently serves as CEO of Leapfrog Bio which is a precision therapeutics company in the oncology space. Prior to Leapfrog, Mr. Vontz served as CEO to BlackThorn Therapeutics (now Neumora Therapeutics: NMRA) and as President and CEO of Topica Pharmaceuticals, Inc., a private clinical stage therapeutics company focused on antifungal therapy. Mr. Vontz served as President & COO of Connetics Corporation, a public specialty pharmaceutical company from 1999-2007. From 1987 – 1999 Mr. Vontz spent 12 years at Genentech in various senior marketing and product development roles. Mr. Vontz got his start in the pharmaceutical industry with Merck, Sharp and Dohme where he worked from 1985-1987 in sales and sales management. Mr. Vontz has a Bachelor of Science degree in Chemistry from the University of Florida and a Masters in Business Administration from the Haas School of Business at the University of California at Berkeley.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.